Federal
Register Notices > Importers
>
Sigma Aldrich Manufacturing LLC
FR Doc E7-3297 [Federal Register: February 27, 2007 (Volume 72, Number 38)]
[Notices] [Page 8793] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr27fe07-131]
[[Page 8793]]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21
U.S.C. 958(i), the Attorney General shall, prior to issuing
a registration under this Section to a bulk manufacturer of a controlled
substance in schedule I or II and prior to issuing a regulation under 21
U.S.C.
952(a) authorizing the importation of such a substance, provide manufacturers
holding registrations for the bulk manufacture of the substance an opportunity
for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
January 9, 2007, Sigma Aldrich Manufacturing LLC., Subsidiary of Sigma-Aldrich
Company, 3500 Dekalb Street, St. Louis, Missouri 63118, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered as an
importer of the basic classes of controlled substances listed in schedule I
and II:
Drug
|
Schedule
|
Cathinone (1235)
|
I
|
Methcathinone (1237)
|
I
|
Aminorex (1585)
|
I
|
Gamma Hydroxybutyric Acid (2010)
|
I
|
Methaqualone (2565)
|
I
|
Ibogaine (7260)
|
I
|
Lysergic acid diethylamide (7315)
|
I
|
Marihuana (7360)
|
I
|
Tetrahydrocannabinols (7370)
|
I
|
Mescaline (7381)
|
I
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)
|
I
|
3,4-Methylenedioxy-N-ethylamphetamine (7404)
|
I
|
3,4-Methylenedioxymethamphetamine (MDMA) (7405)
|
I
|
4-Methoxyamphetamine (7411)
|
I
|
Bufotenine (7433)
|
I
|
Diethyltryptamine (7434)
|
I
|
Dimethyltryptamine (7435)
|
I
|
Psilocybin (7437)
|
I
|
Psilocyn (7438)
|
I
|
N-Ethyl-1-phenylcyclohexylamine (7455)
|
I
|
N-Benzylpiperazine (BZP) (7493)
|
I
|
Trifluoromethylphenyl Piperazine (7494)
|
I
|
Heroin (9200)
|
I
|
Normorphine (9313)
|
I
|
Etonitazene (9624)
|
I
|
Amphetamine (1100)
|
II
|
Methamphetamine (1105)
|
II
|
Methylphenidate (1724)
|
II
|
Amobarbital (2125)
|
II
|
Pentobarbital (2270)
|
II
|
Secobarbital (2315)
|
II
|
Glutethimide (2550)
|
II
|
Nabilone (7379)
|
II
|
Phencyclidine (7471)
|
II
|
Cocaine (9041)
|
II
|
Codeine (9050)
|
II
|
Diprenorphine (9058)
|
II
|
Oxycodone (9143)
|
II
|
Hydromorphone (9150)
|
II
|
Diphenoxylate (9170)
|
II
|
Ecgonine (9180)
|
II
|
Ethylmorphine (9190)
|
II
|
Hydrocodone (9193)
|
II
|
Levorphanol (9220)
|
II
|
Meperidine (9230)
|
II
|
Methadone (9250)
|
II
|
Dextropropoxyphene, bulk (non-dosage forms) (9273)
|
II
|
Morphine (9300)
|
II
|
Thebaine (9333)
|
II
|
Opium powdered (9639)
|
II
|
Oxymorphone (9652)
|
II
|
Fentanyl (9801)
|
II
|
The company plans to import the listed controlled substances for sale to
research facilities for drug testing and analysis. Any bulk manufacturer who
is presently, or is applying to be, registered with DEA to manufacture such
basic classes of controlled substances may file comments or objections to the
issuance of the proposed registration and may, at the same time, file a
written request for a hearing on such application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement Administration, Washington, D.C. 20537,
Attention: DEA Federal Register Representative/ODL; or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria,
Virginia 22301; and must be filed no later than March 29, 2007.
This procedure is to be conducted simultaneously with and independent of
the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the Federal Register on September 23, 1975,
(40 FR 43745-46), all applicants for registration to import a basic classes of
any controlled substances listed in schedule I or II are, and will continue to
be required to demonstrate to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21
U.S.C. 958(a), 21
U.S.C. 823(a), and 21 CFR
1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: February 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration.
[FR Doc. E7-3297 Filed 2-26-07; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|